Bausch & Lomb Corp (BLCO)

Insider Trading Filed: 2026-05-07

Key Insights

EVP and CFO Sam Eldessouky disposed of 63,938 common shares on 05/05/2026 at $16 per share through a Rule 10b5-1 transaction, generating approximately $1.02M in proceeds.
The shares were withheld to satisfy tax obligations on vesting restricted share units, indicating this was a net settlement rather than a discretionary sale decision by the executive.
Following the transaction, Eldessouky retains 343,192 shares in direct beneficial ownership, demonstrating continued substantial equity stake in Bausch & Lomb despite the disposition.

Insider Trading Filed: 2026-05-07

Key Insights

Hashad Yehia, EVP of R&D and CMO, received 13,664 common shares on 05/05/2026 through restricted share unit (RSU) vesting, with 16,377 shares withheld for tax obligations at an implied price of $16 per share.
The transaction represents a routine equity compensation vesting event rather than discretionary insider buying, indicating confidence-neutral activity typical for executive compensation arrangements.
Post-transaction beneficial ownership stands at 166,377 common shares held directly, suggesting meaningful but not substantial concentrated ownership by this senior R&D executive.

Insider Trading Filed: 2026-05-07

Key Insights

Frederick Munsch, SVP Controller and CAO, acquired 8,673 common shares on 05/05/2026 at $16 per share through restricted share unit (RSU) vesting rather than open market purchase, indicating compensation-related transaction rather than voluntary insider buying conviction.
Post-transaction beneficial ownership of 89,640 shares represents a modest stake for a senior finance executive, suggesting limited accumulated equity accumulation relative to executive compensation practices.
The transaction involved share withholding for tax obligations on RSU vesting, a routine administrative action that carries neutral sentiment and does not reflect insider market sentiment or strategic positioning in the company.

Insider Trading Filed: 2026-05-07

Key Insights

Luc Bonnefoy, President of Surgical division, sold 11,970 common shares on 05/05/2026 at $16 per share, generating approximately $191,520 in proceeds through a stock withholding transaction related to restricted share unit vesting.
The disposition was executed via tax withholding (code F), indicating this was a forced sale to cover tax obligations rather than a discretionary market sale, which is less concerning for insider sentiment analysis.
Bonnefoy retains 88,031 shares following the transaction, demonstrating continued substantial beneficial ownership and confidence in the company despite the vesting-related sale.
The transaction occurred at $16 per share, providing a market price reference point for BLCO stock valuation as of early May 2026.

Insider Trading Filed: 2026-05-01

Key Insights

Director Russell C. Robertson acquired 1,611 restricted share units (RSUs) on 04/30/2026 at $15.90 per share, valued at approximately $25,635, indicating insider confidence in the company.
Robertson's total beneficial ownership increased to 78,418 shares following this transaction, demonstrating sustained commitment to BLCO as a director-level insider.
The acquisition of RSUs rather than open market purchases suggests this was likely part of a director compensation package or equity incentive plan rather than opportunistic buying.
No derivative securities activity or significant portfolio changes are reported, indicating a routine equity compensation event with no major insider trading signals.

Insider Trading Filed: 2026-05-01

Key Insights

Director John Paulson acquired 1,375 restricted share units (RSUs) at $15.90 per share on 04/30/2026, increasing his direct beneficial ownership to 73,981 shares, indicating continued confidence in BLCO's value.
The acquisition was made through RSUs rather than open market purchase, suggesting this was likely part of a director compensation or equity incentive plan rather than discretionary insider buying.
The filing shows no derivative securities or options activity, with RSUs representing contingent rights that will convert to common shares, indicating standard equity compensation practices for board members.

Insider Trading Filed: 2026-05-01

Key Insights

Director Steven H. Collis acquired 1,415 restricted share units (RSUs) at $15.90 on April 30, 2026, bringing total beneficial ownership to 26,161 shares, indicating continued confidence in company value by leadership.
The acquisition was executed through RSUs rather than open market purchase, which is typical for executive compensation and suggests this is part of a regular equity grant program rather than discretionary insider buying.
RSU-based compensation represents deferred equity that vests over time, aligning insider interests with long-term shareholder value creation rather than short-term stock price movements.

Insider Trading Filed: 2026-05-01

Key Insights

Director Alfonso Eduardo acquired 1,375 restricted share units (RSUs) at $15.90 per share on 04/30/2026, bringing total beneficial ownership to 15,230 shares, indicating continued insider confidence in the company.
The acquisition was made through RSUs rather than open market purchases, suggesting this was likely a compensation-related grant rather than discretionary buying, which is typical for board compensation.
The relatively modest transaction size and RSU structure (as opposed to significant open market buying) indicates this is routine director compensation rather than a signal of major bullish sentiment from insiders.

Current Report Filed: 2026-04-29

Key Insights

Bausch & Lomb announced Q1 2026 financial results on April 29, 2026, providing quarterly performance data that investors can use to assess operational trends and market positioning in the eye care sector.
The filing is a routine earnings announcement with limited substantive disclosures beyond the press release attachment; no material agreements, guidance changes, or significant corporate events are detailed in the 8-K itself.
As a non-emerging growth company, Bausch & Lomb maintains standard SEC reporting obligations and does not benefit from extended transition periods for new accounting standards, indicating mature company status with full compliance requirements.

Quarterly Report Filed: 2026-04-29

Key Insights

The filing contains extensive segment and reserve accounting data across multiple quarters (Q1 2026, Q1 2025, full year 2024-2025), suggesting detailed tracking of product performance and revenue reserves including discounts, allowances, and rebates.
Recent acquisition activity is documented including the Whitecap Biosciences acquisition (January 2025) and November 2025 acquisitions, indicating an active M&A strategy to expand the product portfolio and market reach.
The company maintains hedging instruments including currency swaps designated as net investment hedges and foreign exchange contracts, reflecting significant international operations exposure that requires active currency risk management.
The filing shows comprehensive fair value measurement disclosures across multiple levels (Level 1-3 inputs), indicating complex financial instruments and valuations that may require careful investor scrutiny of valuation methodologies.

Insider Trading Filed: 2026-04-27

Key Insights

Andrew J. Stewart, President of GPIC, disposed of 4,216 common shares on 04/24/2026 at $15.82 per share through a tax withholding transaction related to restricted share unit vesting, reducing his direct holdings to 86,433 shares.
The transaction was executed via Rule 10b5-1 plan mechanics (share withholding for tax obligations), indicating this was a forced sale rather than a discretionary sell decision, which limits its significance as an insider sentiment indicator.
Stewart maintains a substantial direct ownership position of 86,433 shares following this transaction, suggesting continued confidence in BLCO despite the modest net reduction from RSU vesting tax obligations.

Insider Trading Filed: 2026-04-27

Key Insights

EVP & Chief Legal Officer Robert D Bailey sold 15,806 common shares on 04/24/2026 at $15.82 per share, representing a modest disposition that appears to be a tax withholding event rather than a discretionary sale.
The transaction involved shares withheld to satisfy tax obligations upon vesting of restricted share units, indicating compensation-related activity rather than a loss of confidence in the company.
Bailey retains 230,684 shares in direct beneficial ownership following the transaction, demonstrating substantial continued investment in Bausch & Lomb despite the RSU vesting and tax withholding event.

Insider Trading Filed: 2026-03-04

Key Insights

The reporting person, Thomas W. Ross Sr., acquired 4,500 common shares of Bausch & Lomb Corp (BLCO) in an open market purchase, increasing his direct beneficial ownership to 69,391 shares.
In addition to the open market purchase, Ross also received 4,500 matching restricted share units (MRSUs) as part of the company's matching share program, which will vest over the next three years.
The open market purchase was executed at a weighted average price of $17.679 per share, suggesting confidence in the company's stock performance.

Insider Trading Filed: 2026-03-03

Key Insights

Insider Eduardo Alfonso purchased 4,300 shares of Bausch & Lomb Corp (BLCO) at $17.90 per share, indicating his confidence in the company's future prospects.
The company granted Eduardo Alfonso an additional 4,300 restricted share units (RSUs) as part of a matching share program, further aligning his interests with shareholders.
The insider purchases and RSU grants suggest a positive sentiment from the company's leadership regarding Bausch & Lomb's business and growth potential.

Insider Trading Filed: 2026-03-03

Key Insights

Insider Andrew C. von Eschenbach, a director of Bausch & Lomb Corp, purchased 4,364 common shares on the open market at $18.305 per share, indicating his confidence in the company's prospects.
The reporting person also received 4,364 matching restricted share units (MRSUs) as part of the company's matching share program, which will vest over the next three years, further aligning his interests with shareholders.
The insider's purchase and receipt of MRSUs suggest a positive outlook on the company's future performance and potential for shareholder value creation.

Insider Trading Filed: 2026-03-02

Key Insights

The reporting person, A. Robert D. Bailey, the EVP & Chief Legal Officer of Bausch & Lomb Corp (BLCO), disposed of 5,856 common shares through tax withholding transactions on February 26 and 27, 2026.
The reported transactions suggest that the reporting person may be managing his equity position in the company, potentially for tax planning or other financial purposes.
The total number of common shares beneficially owned by the reporting person decreased from 219,751 to 217,290 following the reported transactions.

Insider Trading Filed: 2026-03-02

Key Insights

The reporting person, Sam Eldessouky, is the Executive Vice President and Chief Financial Officer of Bausch & Lomb Corporation, indicating he holds a significant leadership role within the company.
Eldessouky has disposed of a large number of company shares over a two-day period, selling 7,062 shares on February 26, 2026 and an additional 15,507 and 51,470 shares on February 27, 2026, likely to cover tax withholding obligations on vesting of restricted stock units.
The sale of a total of 74,039 shares by the CFO represents a significant reduction in his beneficial ownership, from 466,107 shares to 399,130 shares, or approximately a 14% decrease in his stake in the company.

Insider Trading Filed: 2026-03-02

Key Insights

Brent L. Saunders, the CEO and Chairman of Bausch & Lomb Corp, has disposed of a significant number of common shares through share withholding to satisfy tax obligations, indicating potential liquidity needs or portfolio rebalancing.
The insider selling activity accounts for approximately 2.3% of Saunders' total beneficial ownership in the company, which could signal a shift in his confidence or investment strategy.
Investors should monitor any further insider selling activity and evaluate its potential impact on the company's leadership and investor sentiment.

Insider Trading Filed: 2026-02-27

Key Insights

The reporting person, Luc Bonnefoy, was granted 30,373 restricted share units (RSUs) under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, which are scheduled to vest over the next three years.
This grant of RSUs indicates that the reporting person, who serves as the President of the Surgical business unit, has been awarded additional equity compensation, potentially aligning his interests with those of Bausch & Lomb's shareholders.
The reporting person's total direct ownership of Bausch & Lomb's common shares has increased to 117,937 following this RSU grant, suggesting a commitment to the company's long-term success.

Insider Trading Filed: 2026-02-27

Key Insights

The reporting person, Frederick Munsch, was granted 18,253 restricted share units (RSUs) under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan. This indicates that the company is incentivizing a key executive through equity-based compensation.
The RSUs granted to Munsch will vest over a three-year period, with one-third vesting on each of the first three anniversaries of the grant date. This suggests a long-term focus on retaining and aligning the executive's interests with those of shareholders.
Munsch's direct ownership of Bausch & Lomb's common shares increased to 108,484 shares following this grant, indicating his substantial stake in the company's performance.

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Important Information